BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Site Heads / General Managers / Vice Presidents from 24 Sites across the BMAC Community came together to sign the BMAC Vision Zero Pledge on 11th Feb 2026 during its 91st BMAC Quarterly Meeting. BMAC welcomed an additional three members to the community namely Astra Zeneca, WuXi Biologics and WuXi XDC.
Three BMAC companies were proud recipients of the WSH CARE Award, a prestigious recognition presented by the Ministry of Manpower (MOM) and the Workplace Safety and Health (WSH) Council. The WSH CARE Award honors organizations that have demonstrated exemplary commitment to fostering mental well-being and a caring workplace culture.
The Singapore Eye Research Institute (SERI) and Santen Pharmaceutical Co., Ltd., a global pharmaceutical company committed to eye health headquartered in Osaka, Japan have launched the Santen–SERI Open Innovation Center (SONIC) 2.0, a next-generation research collaboration designed to accelerate translational development of first-in-class, disease-modifying therapies for vision-threatening eye diseases.
Global pharma companies are looking to Asia for innovation as they consider what’s next to bolster their pipelines, including sourcing of “Best-in-Class” and “First-in-Class” assets that are high quality, robust, pre-clinical, and built on human data.
AstraZeneca plans to hire over 800 employees in Singapore for highly skilled roles ranging from engineering, quality, technical services to global supply chain, as it begins construction of its manufacturing facility for antibody drug conjugates (ADCs), treatments that deliver highly potent cancer-killing agents directly to cancer cells through targeted antibodies.
The United States and Europe have traditionally anchored the global biotechnology (biotech) industry, with the combination of robust academic science, ready venture capital, and regulatory influence making them natural centres for innovation.
International biotech venture capital (VC) firms are flocking to Singapore, drawn by the Asia-Pacific region’s growing life sciences sector, with one more European VC confirmed to set up operations before year-end.
MSD’s Singapore operations are proving that life-saving science can go hand in hand with ambitious climate action.
At its manufacturing site here, the global healthcare company has made energy efficiency and carbon reduction part of daily operations, setting a clear benchmark for environmental stewardship in the industry.
Leveraging innovation and a strong culture of sustainability, Novartis Singapore Pharmaceutical Manufacturing (NSPM) aims to cross the significant milestone of carbon neutrality for Scope 1 and 2 emissions at its Tuas facility.
When Chugai Pharmaceutical set up its first overseas research base in Singapore in 2012, it brought with it a bold ambition: to turn cutting-edge science into breakthrough therapies for patients everywhere.